Justin Walsh
Stock Analyst at Jones Trading
(2.87)
# 1,774
Out of 5,058 analysts
37
Total ratings
40%
Success rate
11.2%
Average return
Main Sectors:
Stocks Rated by Justin Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines | Initiates: Buy | $83 | $189.32 | -56.16% | 1 | Sep 18, 2025 | |
| LNTH Lantheus Holdings | Maintains: Buy | $109 → $84 | $52.79 | +59.12% | 10 | Sep 16, 2025 | |
| VNRX VolitionRx | Initiates: Buy | $3 | $0.33 | +815.47% | 1 | Jun 10, 2025 | |
| BLRX BioLineRx | Upgrades: Buy | $12 | $3.33 | +260.36% | 3 | May 30, 2025 | |
| CLNN Clene | Initiates: Buy | $30 | $8.65 | +246.82% | 1 | Apr 23, 2025 | |
| MNPR Monopar Therapeutics | Downgrades: Hold | n/a | $83.00 | - | 1 | Apr 2, 2025 | |
| SER Serina Therapeutics | Initiates: Buy | $11 | $3.86 | +184.68% | 1 | Mar 11, 2025 | |
| ANRO Alto Neuroscience | Initiates: Buy | $18 | $15.54 | +15.83% | 1 | Dec 16, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $42 | $26.88 | +56.25% | 1 | Oct 18, 2024 | |
| CATX Perspective Therapeutics | Maintains: Buy | $15 → $22 | $2.30 | +856.52% | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.58 | +249.34% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.32 | +362.96% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $4 | $0.64 | +526.17% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $3.72 | +437.63% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $360 | $7.82 | +4,503.58% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $440 | $1.12 | +39,185.71% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $0.49 | +15,203.00% | 1 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $20 | $39.60 | -49.49% | 1 | May 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $440 → $200 | $1.13 | +17,599.12% | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $4.90 | +104.08% | 1 | Jan 19, 2022 |
Praxis Precision Medicines
Sep 18, 2025
Initiates: Buy
Price Target: $83
Current: $189.32
Upside: -56.16%
Lantheus Holdings
Sep 16, 2025
Maintains: Buy
Price Target: $109 → $84
Current: $52.79
Upside: +59.12%
VolitionRx
Jun 10, 2025
Initiates: Buy
Price Target: $3
Current: $0.33
Upside: +815.47%
BioLineRx
May 30, 2025
Upgrades: Buy
Price Target: $12
Current: $3.33
Upside: +260.36%
Clene
Apr 23, 2025
Initiates: Buy
Price Target: $30
Current: $8.65
Upside: +246.82%
Monopar Therapeutics
Apr 2, 2025
Downgrades: Hold
Price Target: n/a
Current: $83.00
Upside: -
Serina Therapeutics
Mar 11, 2025
Initiates: Buy
Price Target: $11
Current: $3.86
Upside: +184.68%
Alto Neuroscience
Dec 16, 2024
Initiates: Buy
Price Target: $18
Current: $15.54
Upside: +15.83%
Rapport Therapeutics
Oct 18, 2024
Initiates: Buy
Price Target: $42
Current: $26.88
Upside: +56.25%
Perspective Therapeutics
May 16, 2024
Maintains: Buy
Price Target: $15 → $22
Current: $2.30
Upside: +856.52%
May 10, 2024
Initiates: Buy
Price Target: $16
Current: $4.58
Upside: +249.34%
Apr 17, 2024
Initiates: Buy
Price Target: $20
Current: $4.32
Upside: +362.96%
Sep 7, 2023
Reinstates: Buy
Price Target: $4
Current: $0.64
Upside: +526.17%
Sep 6, 2023
Initiates: Buy
Price Target: $20
Current: $3.72
Upside: +437.63%
May 16, 2023
Initiates: Buy
Price Target: $360
Current: $7.82
Upside: +4,503.58%
Feb 10, 2023
Initiates: Buy
Price Target: $440
Current: $1.12
Upside: +39,185.71%
Oct 7, 2022
Initiates: Buy
Price Target: $75
Current: $0.49
Upside: +15,203.00%
May 20, 2022
Maintains: Buy
Price Target: $17 → $20
Current: $39.60
Upside: -49.49%
Apr 5, 2022
Maintains: Buy
Price Target: $440 → $200
Current: $1.13
Upside: +17,599.12%
Jan 19, 2022
Initiates: Buy
Price Target: $10
Current: $4.90
Upside: +104.08%